Benign paroxysmal positonal vertigo: A clinical study.
Summary--Ru-Vert, a combination product, containing in each tablet, 25 mg of pentylenetetrazol, 12.5 mg of pheniramine maleate, and 50 mg of nictonic acid, was evaluated in the treatment of seventeen patients with benign paroxysmal positional vertigo. The study was double-blind with crossover. Ru-Vert at a dosage of two tablets t.i.d. was found to reduce significantly the nystagmus and the vertigo induced by Hallpike maneuvers in these patients.
D000328:Adult; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004584:Electronystagmography; D005260:Female; D006801:Humans; D008297:Male; D008298:Maleates / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D009759:Nystagmus, Pathologic / Q000150:complications / Q000175:diagnosis; D010433:Pentylenetetrazole / Q000008:administration & dosage / Q000627:therapeutic use; D010632:Pheniramine / Q000008:administration & dosage / Q000627:therapeutic use*; D011187:Posture; D013607:Tablets; D014717:Vertigo / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
D004338:Drug Combinations; D008298:Maleates; D009539:Nicotinic Acids; D013607:Tablets; D010632:Pheniramine; D010433:Pentylenetetrazole